CERE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.10%

Insider Buying (Last 12 Months): $2,510,922.12

Insider Selling (Last 12 Months): $19,428,510.25

Cerevel Therapeutics Insider Trading History Chart

Cerevel Therapeutics Share Price & Price History

^$20.10

▼ -0.53 (-2.57%)

As of 09/22/2023 12:21 PM ET

Days: 30 | 90 | 365

U.S. Loses to China in Shocking WAR GAMES

From Behind the Markets | Ad

=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

Get the name of the stock here

Cerevel Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/7/2023	N Anthony Coles	Director	Sell	50,000	$24.07	$1,203,500.00	2,704
8/4/2023	Paul D Burgess	Insider	Buy	21,880	$22.93	$501,708.40	21,880
8/3/2023	Ronald C Renaud Jr	CEO	Buy	83,857	$23.96	$2,009,213.72	83,857
7/11/2023	N Anthony Coles	Director	Sell	50,000	$30.03	$1,501,500.00	2,704
6/15/2023	Marijn E Dekkers	Director	Sell	200,000	$34.43	$6,886,000.00	402,326
6/2/2023	Mark Bodenrader	Insider	Sell	1,895	$32.95	$62,440.25	5,522
6/1/2023	N Anthony Coles	CEO	Sell	50,000	$32.60	$1,630,000.00	2,704
5/4/2023	N Anthony Coles	CEO	Sell	50,000	$31.47	$1,573,500.00	2,704
4/11/2023	N Anthony Coles	CEO	Sell	50,000	$25.06	$1,253,000.00	2,704
3/3/2023	N Anthony Coles	CEO	Sell	3,000	$27.19	$81,570.00	2,704
2/7/2023	N Anthony Coles	CEO	Sell	50,000	$33.13	$1,656,500.00	2,704
1/5/2023	N Anthony Coles	CEO	Sell	50,000	$29.94	$1,497,000.00	2,704
12/9/2022	N Anthony Coles	CEO	Sell	50,000	$26.67	$1,333,500.00	2,704
10/4/2022	John Renger	Insider	Sell	25,000	$30.00	$750,000.00	2,704
9/12/2022	Deval L. Patrick	Director	Sell	47,705	$30.78	$1,468,359.90
9/8/2022	Abraham Ceesay	President	Sell	19,210	$32.50	$624,325.00
8/22/2022	Abraham Ceesay	President	Sell	9,605	$32.50	$312,162.50
8/16/2022	Perceptive Advisors Llc	Director	Buy	1,425,000	$35.00	$49,875,000.00	6,511,727
8/10/2022	John Renger	Insider	Sell	55,000	$40.50	$2,227,500.00	2,704
7/20/2022	John Renger	Insider	Sell	25,000	$30.00	$750,000.00	2,704
7/5/2022	John Renger	Insider	Sell	25,000	$30.00	$750,000.00	2,704
4/13/2022	John Renger	Insider	Sell	45,000	$34.65	$1,559,250.00	1,980
3/29/2022	John Renger	Insider	Sell	10,000	$35.00	$350,000.00
3/18/2022	John Renger	Insider	Sell	20,000	$32.50	$650,000.00
3/16/2022	John Renger	Insider	Sell	25,000	$30.00	$750,000.00
2/9/2022	John Renger	Insider	Sell	25,000	$30.00	$750,000.00
12/27/2021	John Renger	Insider	Sell	4,127	$35.00	$144,445.00
12/23/2021	John Renger	Insider	Sell	5,873	$35.00	$205,555.00
12/21/2021	John Renger	Insider	Sell	7,300	$32.50	$237,250.00
12/17/2021	John Renger	Insider	Sell	7,122	$32.50	$231,465.00
12/15/2021	John Renger	Insider	Sell	25,000	$30.02	$750,500.00
11/10/2021	John Renger	Insider	Sell	55,000	$39.86	$2,192,300.00
8/25/2021	Perceptive Advisors Llc	Director	Buy	61,387	$28.57	$1,753,826.59
8/23/2021	Perceptive Advisors Llc	Director	Buy	44,437	$25.78	$1,145,585.86
7/7/2021	Perceptive Advisors Llc	Director	Buy	200,000	$25.00	$5,000,000.00
6/17/2021	Gabrielle Sulzberger	Director	Buy	21,084	$13.06	$275,357.04	35,354

BREAKING: The truth about war with China

From Behind the Markets | Ad

Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.

Get the list of risky investments here >>>

SEC Filings (Institutional Ownership Changes) for Cerevel Therapeutics (NASDAQ:CERE)

87.73% of Cerevel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cerevel Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/21/2023	Barclays PLC	131,342	$4.18M	0.0%	-78.1%	0.083%
8/24/2023	Perceptive Advisors LLC	10,088,385	$320.71M	9.3%	+54.9%	6.406%
8/21/2023	Affinity Asset Advisors LLC	550,000	$17.48M	6.0%	+44.7%	0.349%
8/21/2023	California State Teachers Retirement System	75,724	$2.41M	0.0%	-0.7%	0.048%
8/15/2023	Alliancebernstein L.P.	90,540	$2.88M	0.0%	+34.7%	0.057%
8/15/2023	Wells Fargo & Company MN	63,629	$2.02M	0.0%	+4.5%	0.040%
8/15/2023	Eventide Asset Management LLC	490,000	$15.58M	0.3%	+57.1%	0.311%
8/15/2023	Woodline Partners LP	794,919	$25.27M	0.3%	+30.0%	0.505%
8/15/2023	Goldman Sachs Group Inc.	363,704	$11.56M	0.0%	-3.5%	0.231%
8/15/2023	Lazard Asset Management LLC	7,336	$0.23M	0.0%	-9.2%	0.005%
8/15/2023	Royal Bank of Canada	4,050	$0.13M	0.0%	+18.6%	0.003%
8/14/2023	NinePointTwo Capital LLC	8,151	$0.26M	0.1%	N/A	0.005%
8/14/2023	Tower Research Capital LLC TRC	4,262	$0.14M	0.0%	+59.4%	0.003%
8/14/2023	Schonfeld Strategic Advisors LLC	66,390	$2.11M	0.0%	N/A	0.042%
8/14/2023	State of Wisconsin Investment Board	54,747	$1.74M	0.0%	-5.1%	0.035%
8/14/2023	State Street Corp	2,768,277	$88M	0.0%	-11.8%	1.758%
8/14/2023	Jefferies Financial Group Inc.	25,000	$0.80M	0.0%	-50.0%	0.016%
8/14/2023	UniSuper Management Pty Ltd	97,429	$3.10M	0.0%	N/A	0.062%
8/14/2023	Nuveen Asset Management LLC	149,716	$4.76M	0.0%	+4.8%	0.095%
8/14/2023	Polar Capital Holdings Plc	910,762	$28.95M	0.2%	+18.5%	0.578%
8/14/2023	Graham Capital Management L.P.	10,344	$0.33M	0.0%	N/A	0.007%
8/11/2023	Credit Suisse AG	72,773	$2.31M	0.0%	+31.2%	0.046%
8/11/2023	BlackRock Inc.	4,832,707	$153.63M	0.0%	+7.8%	3.081%
8/11/2023	Ameritas Investment Partners Inc.	5,110	$0.16M	0.0%	+11.5%	0.003%
8/11/2023	State Board of Administration of Florida Retirement System	17,570	$0.56M	0.0%	+24.9%	0.011%
8/11/2023	The Manufacturers Life Insurance Company	146,096	$4.64M	0.0%	+14.7%	0.093%
8/11/2023	Guggenheim Capital LLC	13,367	$0.43M	0.0%	+12.1%	0.009%
8/11/2023	Geode Capital Management LLC	1,346,029	$42.79M	0.0%	+7.0%	0.858%
8/11/2023	Artal Group S.A.	1,638,858	$52.10M	1.6%	-14.4%	1.045%
8/11/2023	Sei Investments Co.	14,960	$0.48M	0.0%	+17.8%	0.010%
8/11/2023	E Fund Management Co. Ltd.	9,501	$0.30M	0.0%	-20.4%	0.006%
8/11/2023	PNC Financial Services Group Inc.	5,640	$0.18M	0.0%	N/A	0.004%
8/11/2023	Northern Trust Corp	583,278	$18.54M	0.0%	+5.4%	0.372%
8/11/2023	ExodusPoint Capital Management LP	15,245	$0.49M	0.0%	N/A	0.010%
8/10/2023	MetLife Investment Management LLC	32,786	$1.04M	0.0%	+7.8%	0.021%
8/10/2023	ProShare Advisors LLC	8,048	$0.26M	0.0%	N/A	0.005%
8/10/2023	Profund Advisors LLC	32,605	$1.04M	0.1%	-17.1%	0.021%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	33,888	$1.08M	0.0%	+3.4%	0.022%
8/10/2023	Charles Schwab Investment Management Inc.	501,983	$15.96M	0.0%	+3.1%	0.320%
8/10/2023	Citigroup Inc.	68,279	$2.17M	0.0%	-59.5%	0.044%
8/9/2023	TD Asset Management Inc	203,449	$6.47M	0.0%	+12.3%	0.130%
8/9/2023	Swiss National Bank	136,400	$4.34M	0.0%	+1.0%	0.087%
8/8/2023	Rhumbline Advisers	88,268	$2.81M	0.0%	+5.4%	0.056%
8/7/2023	Principal Financial Group Inc.	26,572	$0.85M	0.0%	-5.7%	0.017%
8/4/2023	American International Group Inc.	29,785	$0.95M	0.0%	+7.7%	0.019%
8/3/2023	Barclays PLC	131,342	$4.18M	0.0%	-78.1%	0.084%
8/3/2023	Bank of New York Mellon Corp	260,100	$8.27M	0.0%	+10.4%	0.166%
8/2/2023	State of New Jersey Common Pension Fund D	73,492	$2.34M	0.0%	N/A	0.047%
8/2/2023	Handelsbanken Fonder AB	11,600	$0.37M	0.0%	+28.9%	0.007%
8/1/2023	Arizona State Retirement System	17,601	$0.56M	0.0%	-2.9%	0.011%
7/31/2023	Duality Advisers LP	16,094	$0.51M	0.1%	N/A	0.010%
7/31/2023	Strs Ohio	10,200	$0.32M	0.0%	+161.5%	0.007%
7/27/2023	Victory Capital Management Inc.	7,377	$0.24M	0.0%	N/A	0.005%
7/27/2023	Virtu Financial LLC	14,053	$0.45M	0.0%	N/A	0.009%
7/19/2023	Teacher Retirement System of Texas	17,000	$0.54M	0.0%	-11.7%	0.011%
7/10/2023	SG Americas Securities LLC	4,556	$0.15M	0.0%	-84.5%	0.003%
5/18/2023	New York State Common Retirement Fund	30,487	$0.74M	0.0%	-26.0%	0.019%
5/16/2023	Hudson Bay Capital Management LP	40,000	$0.98M	0.0%	-20.0%	0.026%
5/16/2023	State Street Corp	3,137,586	$76.53M	0.0%	-8.4%	2.001%
5/16/2023	Squarepoint Ops LLC	32,300	$0.79M	0.0%	-40.0%	0.021%
5/16/2023	Geode Capital Management LLC	1,257,920	$30.68M	0.0%	+4.5%	0.802%
5/16/2023	AQR Capital Management LLC	13,651	$0.33M	0.0%	-16.8%	0.009%
5/16/2023	Balyasny Asset Management L.P.	349,602	$8.53M	0.0%	N/A	0.223%
5/16/2023	Boone Capital Management LLC	300,000	$7.32M	3.4%	N/A	0.191%
5/15/2023	Affinity Asset Advisors LLC	380,000	$9.27M	3.1%	+76.7%	0.242%
5/15/2023	Two Sigma Investments LP	13,700	$0.33M	0.0%	+71.3%	0.009%
5/15/2023	Deutsche Bank AG	41,333	$1.01M	0.0%	+38.7%	0.026%
5/15/2023	Price T Rowe Associates Inc. MD	4,799,707	$117.07M	0.0%	-0.1%	3.060%
5/15/2023	Hood River Capital Management LLC	572,876	$13.97M	0.5%	-38.0%	0.365%
5/15/2023	AXA S.A.	201,733	$4.92M	0.0%	-0.2%	0.129%
5/12/2023	BlackRock Inc.	4,484,941	$109.39M	0.0%	+0.1%	2.863%
5/12/2023	Bank of America Corp DE	275,376	$6.72M	0.0%	+22.6%	0.176%
5/12/2023	Finepoint Capital LP	539,445	$13.16M	5.0%	+4.3%	0.344%
5/12/2023	Sei Investments Co.	12,697	$0.31M	0.0%	-44.9%	0.008%
5/12/2023	Dark Forest Capital Management LP	3,093	$75K	0.0%	N/A	0.002%
5/12/2023	Charles Schwab Investment Management Inc.	486,983	$11.88M	0.0%	+0.3%	0.311%
5/12/2023	Profund Advisors LLC	39,316	$0.96M	0.1%	N/A	0.025%
5/12/2023	HighTower Advisors LLC	74,538	$1.81M	0.0%	-0.7%	0.048%
5/11/2023	FMR LLC	23,467,258	$572.37M	0.1%	+0.2%	14.980%
5/11/2023	American Century Companies Inc.	254,001	$6.18M	0.0%	+1.1%	0.162%
5/11/2023	Rhumbline Advisers	83,722	$2.04M	0.0%	+5.0%	0.053%
5/11/2023	E Fund Management Co. Ltd.	11,932	$0.29M	0.0%	-4.6%	0.008%
5/11/2023	Guggenheim Capital LLC	11,924	$0.29M	0.0%	+13.6%	0.008%
5/10/2023	Swiss National Bank	135,000	$3.29M	0.0%	-10.3%	0.086%
5/9/2023	Principal Financial Group Inc.	28,179	$0.69M	0.0%	-5.7%	0.018%
5/9/2023	Tower Research Capital LLC TRC	2,674	$65K	0.0%	-28.6%	0.002%
5/9/2023	Bank of New York Mellon Corp	235,698	$5.75M	0.0%	+0.4%	0.150%
5/9/2023	California State Teachers Retirement System	76,246	$1.86M	0.0%	-1.1%	0.049%
5/8/2023	Federated Hermes Inc.	1,924,972	$46.95M	0.1%	-32.9%	1.229%
5/4/2023	Barclays PLC	601,054	$14.66M	0.0%	+31.6%	0.384%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	32,772	$0.80M	0.0%	+32.1%	0.021%
5/2/2023	Amalgamated Bank	8,096	$0.20M	0.0%	-15.3%	0.005%
4/28/2023	SG Americas Securities LLC	29,354	$0.72M	0.0%	+102.4%	0.019%
4/27/2023	Arizona State Retirement System	18,118	$0.44M	0.0%	+3.1%	0.012%
3/23/2023	ETF Managers Group LLC	11,313	$0.36M	0.0%	N/A	0.007%
3/23/2023	MetLife Investment Management LLC	30,419	$0.96M	0.0%	+5.5%	0.019%
2/28/2023	Voya Investment Management LLC	21,479	$0.68M	0.0%	+2.4%	0.014%
2/15/2023	MetLife Investment Management LLC	30,419	$0.96M	0.0%	+5.5%	0.019%
2/15/2023	Lazard Asset Management LLC	10,158	$0.32M	0.0%	N/A	0.006%
2/15/2023	State of Wisconsin Investment Board	62,467	$1.97M	0.0%	+4.9%	0.040%

Data available starting January 2016

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $20.10

$20.10

$20.65

50 Day Range

MA: $24.55

$20.55

$30.73

52 Week Range

Now: $20.10

$20.10

$35.98

Volume

85,076 shs

Average Volume

610,079 shs

Market Capitalization

$3.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Who are the company insiders with the largest holdings of Cerevel Therapeutics?: Cerevel Therapeutics' top insider investors include:
Perceptive Advisors Llc (Director)
Marijn E Dekkers (Director)
Ronald C Renaud Jr (CEO)
Paul D Burgess (Insider)
Mark Bodenrader (Insider)
John Renger (Insider)
N Anthony Coles (CEO)
N Anthony Coles (Director)
Abraham Ceesay (President)
Deval L Patrick (Director)
Learn More about top insider investors at Cerevel Therapeutics.
Who are the major institutional investors of Cerevel Therapeutics?: Cerevel Therapeutics' top institutional shareholders include:
Perceptive Advisors LLC — 6.41%
BlackRock Inc. — 3.08%
State Street Corp — 1.76%
Artal Group S.A. — 1.04%
Geode Capital Management LLC — 0.86%
Polar Capital Holdings Plc — 0.58%
Learn More about top institutional investors of Cerevel Therapeutics stock.
Which major investors are selling Cerevel Therapeutics stock?: In the previous quarter, CERE stock was sold by these institutional investors:
Barclays PLC
Barclays PLC
State Street Corp
Artal Group S.A.
Citigroup Inc.
Simplex Trading LLC
Wolverine Trading LLC
Jefferies Financial Group Inc.
During the last year, company insiders that have sold Cerevel Therapeutics company stock include:
Perceptive Advisors Llc (Director)
Marijn E Dekkers (Director)
Ronald C Renaud Jr (CEO)
Paul D Burgess (Insider)
Mark Bodenrader (Insider)
Learn More investors selling Cerevel Therapeutics stock.
Which major investors are buying Cerevel Therapeutics stock?: In the previous quarter, CERE stock was purchased by institutional investors including:
Perceptive Advisors LLC
BlackRock Inc.
Woodline Partners LP
Eventide Asset Management LLC
Affinity Asset Advisors LLC
Polar Capital Holdings Plc
UniSuper Management Pty Ltd
Geode Capital Management LLC
In the last year, these company insiders have bought Cerevel Therapeutics stock:
Perceptive Advisors Llc (Director)
Marijn E Dekkers (Director)
Ronald C Renaud Jr (CEO)
Learn More investors buying Cerevel Therapeutics stock.